NO304348B1 - FremgangsmÕte for fremstilling av en medikamentinneholdende doseringsform for bruk ved transmucosal administrering - Google Patents

FremgangsmÕte for fremstilling av en medikamentinneholdende doseringsform for bruk ved transmucosal administrering Download PDF

Info

Publication number: NO304348B1
Authority: NO; Norway
Prior art keywords: drug; patient; mouth; dosage form; drugs
Prior art date: 1989-09-05

Application number

NO920857A

Other languages

English (en)

Norwegian (no)

Other versions

NO920857D0 (no

NO920857L (no

Inventor

Theodore H Stanley

Brian Hague

Original Assignee

Univ Utah Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-05

Filing date

1992-03-04

Publication date

1998-12-07

1992-03-04 Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found

1992-03-04 Publication of NO920857D0 publication Critical patent/NO920857D0/no

1992-04-06 Publication of NO920857L publication Critical patent/NO920857L/no

1998-12-07 Publication of NO304348B1 publication Critical patent/NO304348B1/no

Links

239000003814 drug Substances 0.000 title claims abstract description 327
229940079593 drug Drugs 0.000 title claims abstract description 313
239000002552 dosage form Substances 0.000 title claims abstract description 88
238000004519 manufacturing process Methods 0.000 title claims abstract description 14
239000011159 matrix material Substances 0.000 claims abstract description 95
238000000034 method Methods 0.000 claims abstract description 53
210000004400 mucous membrane Anatomy 0.000 claims abstract description 27
238000010521 absorption reaction Methods 0.000 claims abstract description 17
210000000214 mouth Anatomy 0.000 claims description 46
239000003623 enhancer Substances 0.000 claims description 29
238000002156 mixing Methods 0.000 claims description 19
230000035699 permeability Effects 0.000 claims description 19
238000004090 dissolution Methods 0.000 claims description 18
210000003238 esophagus Anatomy 0.000 claims description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
210000003800 pharynx Anatomy 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 14
239000003833 bile salt Substances 0.000 claims description 13
238000007906 compression Methods 0.000 claims description 13
230000006835 compression Effects 0.000 claims description 13
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
238000007493 shaping process Methods 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 10
229940093761 bile salts Drugs 0.000 claims description 9
239000003961 penetration enhancing agent Substances 0.000 claims description 8
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 7
230000035515 penetration Effects 0.000 claims description 6
210000003296 saliva Anatomy 0.000 claims description 6
239000004094 surface-active agent Chemical class 0.000 claims description 5
AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 4
229920002125 Sokalan® Polymers 0.000 claims description 4
DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
239000004584 polyacrylic acid Substances 0.000 claims description 4
230000003389 potentiating effect Effects 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
150000004671 saturated fatty acids Chemical class 0.000 claims description 4
235000003441 saturated fatty acids Nutrition 0.000 claims description 4
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
239000006172 buffering agent Substances 0.000 claims description 3
239000000203 mixture Substances 0.000 description 51
230000000694 effects Effects 0.000 description 36
239000004615 ingredient Substances 0.000 description 32
239000000126 substance Substances 0.000 description 26
235000009508 confectionery Nutrition 0.000 description 25
NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 16
229960002683 methohexital Drugs 0.000 description 16
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
239000000047 product Substances 0.000 description 14
235000019640 taste Nutrition 0.000 description 14
239000000872 buffer Substances 0.000 description 12
239000000796 flavoring agent Substances 0.000 description 12
239000007788 liquid Substances 0.000 description 11
210000004379 membrane Anatomy 0.000 description 11
239000012528 membrane Substances 0.000 description 11
210000003169 central nervous system Anatomy 0.000 description 10
235000019634 flavors Nutrition 0.000 description 10
230000015556 catabolic process Effects 0.000 description 9
238000006731 degradation reaction Methods 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
239000000843 powder Substances 0.000 description 9
239000002585 base Substances 0.000 description 8
239000008280 blood Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
235000003599 food sweetener Nutrition 0.000 description 8
239000003765 sweetening agent Substances 0.000 description 8
229940124597 therapeutic agent Drugs 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
206010002091 Anaesthesia Diseases 0.000 description 7
206010039897 Sedation Diseases 0.000 description 7
230000037005 anaesthesia Effects 0.000 description 7
239000007937 lozenge Substances 0.000 description 7
230000036280 sedation Effects 0.000 description 7
230000002792 vascular Effects 0.000 description 7
239000001993 wax Substances 0.000 description 7
230000008901 benefit Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
235000019264 food flavour enhancer Nutrition 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
239000004097 EU approved flavor enhancer Substances 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000000949 anxiolytic effect Effects 0.000 description 5
210000000748 cardiovascular system Anatomy 0.000 description 5
239000003925 fat Substances 0.000 description 5
230000008018 melting Effects 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000001624 sedative effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 4
239000005913 Maltodextrin Substances 0.000 description 4
229920002774 Maltodextrin Polymers 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
229940035034 maltodextrin Drugs 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
239000000932 sedative agent Substances 0.000 description 4
230000035882 stress Effects 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
230000009747 swallowing Effects 0.000 description 4
-1 theaurodeoxycholate Chemical compound 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000003139 buffering effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000018044 dehydration Effects 0.000 description 3
238000006297 dehydration reaction Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
239000003292 glue Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000009101 premedication Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010063659 Aversion Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
235000009499 Vanilla fragrans Nutrition 0.000 description 2
244000263375 Vanilla tahitensis Species 0.000 description 2
235000012036 Vanilla tahitensis Nutrition 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
235000010357 aspartame Nutrition 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
235000019658 bitter taste Nutrition 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229940069078 citric acid / sodium citrate Drugs 0.000 description 2
238000002485 combustion reaction Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
230000000857 drug effect Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000001050 lubricating effect Effects 0.000 description 2
239000002075 main ingredient Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
235000014594 pastries Nutrition 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
240000000560 Citrus x paradisi Species 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
240000004670 Glycyrrhiza echinata Species 0.000 description 1
235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
239000004378 Glycyrrhizin Substances 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
244000024873 Mentha crispa Species 0.000 description 1
235000014749 Mentha crispa Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
101710084933 Miraculin Proteins 0.000 description 1
108050004114 Monellin Proteins 0.000 description 1
IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
229940127450 Opioid Agonists Drugs 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
239000004376 Sucralose Substances 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
230000003023 adrenocorticotropic effect Effects 0.000 description 1
229960001391 alfentanil Drugs 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000002882 anti-plaque Effects 0.000 description 1
230000001139 anti-pruritic effect Effects 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
230000009118 appropriate response Effects 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
229940046011 buccal tablet Drugs 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
230000003684 cardiac depression Effects 0.000 description 1
229940000032 cardiovascular system drug Drugs 0.000 description 1
YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 1
229950004689 carfentanil Drugs 0.000 description 1
238000005266 casting Methods 0.000 description 1
239000003576 central nervous system agent Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229940009025 chenodeoxycholate Drugs 0.000 description 1
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
229940009979 dehydrocholate Drugs 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
229940072271 diprivan Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229960000394 droperidol Drugs 0.000 description 1
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
230000005611 electricity Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
229960001690 etomidate Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
229960004949 glycyrrhizic acid Drugs 0.000 description 1
UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
235000019410 glycyrrhizin Nutrition 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
229940010454 licorice Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
229950010274 lofentanil Drugs 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000005399 mechanical ventilation Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 1
229960001620 methohexital sodium Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
229960003793 midazolam Drugs 0.000 description 1
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
239000004223 monosodium glutamate Substances 0.000 description 1
230000004677 mucosal permeability Effects 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
229940000041 nervous system drug Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
229950006124 oxazolam Drugs 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000009894 physiological stress Effects 0.000 description 1
229940023488 pill Drugs 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
230000014860 sensory perception of taste Effects 0.000 description 1
239000002893 slag Substances 0.000 description 1
238000009491 slugging Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
AECTYFQKWPXOSR-DGMAEHPPSA-M sodium;(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 AECTYFQKWPXOSR-DGMAEHPPSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
229940013618 stevioside Drugs 0.000 description 1
OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
235000019202 steviosides Nutrition 0.000 description 1
235000019408 sucralose Nutrition 0.000 description 1
BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
229960004739 sufentanil Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000892 thaumatin Substances 0.000 description 1
235000010436 thaumatin Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
229960003386 triazolam Drugs 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940014499 ursodeoxycholate Drugs 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
229940072690 valium Drugs 0.000 description 1
238000007740 vapor deposition Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
- A23G3/54—Composite products, e.g. layered, coated, filled
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
- A23G3/56—Products with edible or inedible supports, e.g. lollipops
- A23G3/563—Products with edible or inedible supports, e.g. lollipops products with an inedible support, e.g. a stick
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0015—Devices specially adapted for taking medicines
- A61J7/003—Sticks, e.g. lollipops with drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO920857A 1989-09-05 1992-03-04 FremgangsmÕte for fremstilling av en medikamentinneholdende doseringsform for bruk ved transmucosal administrering NO304348B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/403,751 US5288497A (en)	1985-05-01	1989-09-05	Compositions of oral dissolvable medicaments
PCT/US1990/004384 WO1991003237A1 (en)	1989-09-05	1990-08-03	Compositions and methods of manufacture of oral dissolvable medicaments

Publications (3)

Publication Number	Publication Date
NO920857D0 NO920857D0 (no)	1992-03-04
NO920857L NO920857L (no)	1992-04-06
NO304348B1 true NO304348B1 (no)	1998-12-07

Family

ID=23596872

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO920857A NO304348B1 (no)	1989-09-05	1992-03-04	FremgangsmÕte for fremstilling av en medikamentinneholdende doseringsform for bruk ved transmucosal administrering

Country Status (11)

Country	Link
US (1)	US5288497A (de)
EP (2)	EP0490916B1 (de)
JP (1)	JP2717024B2 (de)
AT (2)	ATE177007T1 (de)
AU (2)	AU645265B2 (de)
CA (1)	CA2066423C (de)
DE (2)	DE69023143T2 (de)
DK (2)	DK0490916T3 (de)
ES (2)	ES2133448T3 (de)
NO (1)	NO304348B1 (de)
WO (1)	WO1991003237A1 (de)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5288497A (en) *	1985-05-01	1994-02-22	The University Of Utah	Compositions of oral dissolvable medicaments
US5824334A (en) *	1989-09-05	1998-10-20	University Of Utah Research Foundation	Tobacco substitute
IT1238072B (it) *	1990-01-19	1993-07-03	Sclavo Spa	Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
US5223259A (en) *	1990-09-19	1993-06-29	Lackney Albert M	Securing means for an oral medicament and support therefor
ATE140620T1 (de) *	1991-12-05	1996-08-15	Mallinckrodt Veterinary Inc	Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
US5466464A (en) *	1991-12-24	1995-11-14	Yamanouchi Pharmaceutical Co., Ltd.	Intrabuccally disintegrating preparation and production thereof
GB9212511D0 (en) *	1992-06-12	1992-07-22	Cortecs Ltd	Pharmaceutical compositions
GB9213874D0 (en) *	1992-06-30	1992-08-12	Fisons Plc	Process to novel medicament form
JPH0776527A (ja) *	1993-06-28	1995-03-20	Hayashibara Biochem Lab Inc	半固形製剤とその製造方法
US5549906A (en) *	1993-07-26	1996-08-27	Pharmacia Ab	Nicotine lozenge and therapeutic method for smoking cessation
WO1995003771A1 (en) *	1993-08-03	1995-02-09	Pacific Rim Productions Pty. Ltd.	Treatment of oral ailments
US6352713B1 (en)	1999-12-01	2002-03-05	Drugtech Corporation	Nutritional composition
US6488956B1 (en) *	1994-06-20	2002-12-03	Drugtech Corporation	Multi-vitamin and mineral supplements for women
MA23587A1 (fr) *	1994-06-23	1995-12-31	Procter & Gamble	Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
WO1996000072A1 (en) *	1994-06-23	1996-01-04	The Procter & Gamble Company	Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
AU2702795A (en) *	1994-06-23	1996-01-19	Procter & Gamble Company, The	Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration
GB2325408B (en) *	1994-06-28	1999-01-27	Kenneth Francis Prendergast	Chewing gum formulation comprising ondansetron
GB9423511D0 (en) *	1994-11-22	1995-01-11	Glaxo Wellcome Inc	Compositions
WO1996023507A1 (en) *	1995-02-02	1996-08-08	Chugai Seiyaku Kabushiki Kaisha	Sucralfate preparation
US5788982A (en) *	1995-06-16	1998-08-04	Nadoolman; Wolffe	Method and composition for treating oral pain using capsaicin
GB9517062D0 (en) *	1995-08-18	1995-10-25	Scherer Ltd R P	Pharmaceutical compositions
US5912014A (en) *	1996-03-15	1999-06-15	Unigene Laboratories, Inc.	Oral salmon calcitonin pharmaceutical products
SE9601421D0 (sv) *	1996-04-12	1996-04-12	Astra Ab	New composition
PT906089E (pt)	1996-05-13	2004-01-30	Novartis Consumer Health Sa	Sistema de administracao bucal
US5726154A (en) *	1996-06-28	1998-03-10	University Of Utah Research Foundation	Stabilization and oral delivery of calcitonin
US6255502B1 (en) *	1996-07-11	2001-07-03	Farmarc Nederland B.V.	Pharmaceutical composition containing acid addition salt of basic drug
DE19646392A1 (de) *	1996-11-11	1998-05-14	Lohmann Therapie Syst Lts	Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
US20040023948A1 (en) *	1997-03-24	2004-02-05	Green Richard David	Fast-dispersing dosage form containing 5-HT1 agonists
TW586934B (en) *	1997-05-19	2004-05-11	Sumitomo Pharma	Immunopotentiating composition
US6197331B1 (en)	1997-07-24	2001-03-06	Perio Products Ltd.	Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
US6177282B1 (en) *	1997-08-12	2001-01-23	Mcintyre John A.	Antigens embedded in thermoplastic
GB9717770D0 (en) *	1997-08-21	1997-10-29	Scherer Ltd R P	Pharmaceutical composition
US8765177B2 (en) *	1997-09-12	2014-07-01	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US7153845B2 (en) *	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US6074674A (en) *	1997-10-31	2000-06-13	University Of Kentucky Research Foundation	Formulations for sustained-release of topical anesthetics and methods of making and using same
US7070799B1 (en) *	1998-02-10	2006-07-04	Generex Pharmaceuticals, Inc.	Method for administering insulin to the buccal region
US6221378B1 (en)	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US5997884A (en) *	1998-02-12	1999-12-07	Taylor Pharmaceuticals	Compositions and method for treating migraine
US5981552A (en) *	1998-10-23	1999-11-09	Taylor Pharmaceuticals	Sublingual and buccal compositions of droperidol and method for treating migraine
US5990134A (en) *	1998-08-12	1999-11-23	Taylor Pharmaceuticals	Oral droperidol compositions and method for treating migraine
US6974590B2 (en) *	1998-03-27	2005-12-13	Cima Labs Inc.	Sublingual buccal effervescent
US20030091629A1 (en) *	1998-03-27	2003-05-15	Cima Labs Inc.	Sublingual buccal effervescent
US6103257A (en) *	1998-07-17	2000-08-15	Num-Pop, Inc.	System for delivering pharmaceuticals to the buccal mucosa
US6368625B1 (en)	1998-08-12	2002-04-09	Cima Labs Inc.	Orally disintegrable tablet forming a viscous slurry
ES2211151T3 (es) *	1998-08-19	2004-07-01	Skyepharma Canada Inc.	Dispersiones acuosas inyectables de propofol.
US6344222B1 (en)	1998-09-03	2002-02-05	Jsr Llc	Medicated chewing gum delivery system for nicotine
US6358060B2 (en)	1998-09-03	2002-03-19	Jsr Llc	Two-stage transmucosal medicine delivery system for symptom relief
SE9803240D0 (sv) *	1998-09-24	1998-09-24	Diabact Ab	A pharmaceutical composition having a rapid action
SE9803239D0 (sv) *	1998-09-24	1998-09-24	Diabact Ab	Composition for the treatment of acute pain
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6270781B1 (en)	1999-01-08	2001-08-07	Maxim Pharmaceuticals, Inc.	Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6242473B1 (en)	1999-01-08	2001-06-05	Maxim Pharmaceuticals, Inc.	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6884792B2 (en) *	1999-01-08	2005-04-26	Marvin B. Bacaner	Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
IL144199A0 (en)	1999-01-08	2002-05-23		Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
US6552024B1 (en)	1999-01-21	2003-04-22	Lavipharm Laboratories Inc.	Compositions and methods for mucosal delivery
US8119159B2 (en) *	1999-02-22	2012-02-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
US7658938B2 (en) *	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US20070148228A1 (en) *	1999-02-22	2007-06-28	Merrion Research I Limited	Solid oral dosage form containing an enhancer
US6350432B1 (en)	1999-03-19	2002-02-26	Generex Pharmaceuticals Incorporated	Pressurized container having an aerosolized pharmaceutical composition
US6248760B1 (en) *	1999-04-14	2001-06-19	Paul C Wilhelmsen	Tablet giving rapid release of nicotine for transmucosal administration
WO2000076556A2 (en) *	1999-06-11	2000-12-21	Neorx Corporation	High dose radionuclide complexes for bone marrow suppression
DE19932603A1 (de)	1999-07-13	2001-01-25	Gruenenthal Gmbh	Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren
WO2001013921A1 (en)	1999-08-23	2001-03-01	Ockert David M	Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
WO2001051089A1 (de) *	2000-01-13	2001-07-19	Merck Patent Gmbh	Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
WO2001089476A1 (en) *	2000-05-19	2001-11-29	Npd Llc	Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
US6526993B1 (en) *	2000-09-12	2003-03-04	Eugene C. Wagner	Dental implement with comfit grip
US6365215B1 (en) *	2000-11-09	2002-04-02	International Flavors & Fragrances Inc.	Oral sensory perception-affecting compositions containing dimethyl sulfoxide, complexes thereof and salts thereof
US20020106407A1 (en) *	2000-12-11	2002-08-08	Dennis Coleman	Method and apparatus for treating breakthrough pain
US20020160043A1 (en) *	2001-02-27	2002-10-31	Dennis Coleman	Compositions and method of manufacture for oral dissolvable dosage forms
US20030118628A1 (en) *	2001-04-05	2003-06-26	Tutuncu Nurhan Pinar	Confectionery product having a salivation region and an oral comfort region
USD452145S1 (en)	2001-04-12	2001-12-18	Ramkarran Sukhlall	Gel dispensing device
EP1390383B1 (de) *	2001-05-11	2012-02-29	Isis Pharmaceuticals, Inc.	Antisense-permeationsverstärker
RU2004107501A (ru) *	2001-08-14	2005-02-20	Байотай Терапис Корпорейшн (Fi)	Способ лечения алкоголизма или злоупотребления алкоголем
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030049304A1 (en) *	2001-08-29	2003-03-13	Somani Jitendra Krishan	Quiescently frozen ice products
CA2461661A1 (en) *	2001-10-19	2003-05-01	Maxim Pharmaceuticals, Inc.	Use of histamine to treat liver disease
CA2466083A1 (en) *	2001-11-06	2003-05-15	Maxim Pharmaceuticals, Inc.	Compositions for the treatment of infectious diseases
GB0210397D0 (en) *	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
EP1534302A4 (de) *	2002-08-22	2009-01-07	Nutrition 21 Inc	Argininsilikat/inositol-komplex und seine verwendung
US6592908B1 (en)	2002-09-23	2003-07-15	Albert Crum	Nutritional or therapeutic compositions
US20040115244A1 (en) *	2002-12-17	2004-06-17	Holgate Eric Jamison	Methods and compositions for nicotine replacement therapy
US8088734B2 (en) *	2003-01-21	2012-01-03	Unigene Laboratories Inc.	Oral delivery of peptides
US20080213363A1 (en) *	2003-01-23	2008-09-04	Singh Nikhilesh N	Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20040253307A1 (en) *	2003-02-04	2004-12-16	Brian Hague	Sugar-free oral transmucosal solid dosage forms and uses thereof
US20060062812A1 (en) *	2003-03-11	2006-03-23	Calvin Ross	Novel compositions
US6966252B2 (en)	2003-03-31	2005-11-22	Mcneil-Ppc, Inc.	Hydrophilic substance dispensing device
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
BRPI0302736B8 (pt) *	2003-06-02	2021-05-25	Ems S/A	composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
US20070059346A1 (en) *	2003-07-01	2007-03-15	Todd Maibach	Film comprising therapeutic agents
CA2535803A1 (en) *	2003-08-21	2005-03-03	Transoral Pharmaceuticals, Inc.	Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
US20050042281A1 (en) *	2003-08-21	2005-02-24	Singh Nikhilesh N.	Compositions for delivering therapeutic agents across the oral mucosa
US7282217B1 (en)	2003-08-29	2007-10-16	Kv Pharmaceutical Company	Rapidly disintegrable tablets
US8469036B2 (en)	2003-11-07	2013-06-25	U.S. Smokeless Tobacco Company Llc	Tobacco compositions
US8627828B2 (en) *	2003-11-07	2014-01-14	U.S. Smokeless Tobacco Company Llc	Tobacco compositions
WO2005060960A2 (en) *	2003-12-11	2005-07-07	Maxim Pharmaceuticals, Inc.	Use of histamine to treat bone disease
DE602004031462D1 (de) *	2003-12-31	2011-03-31	Cima Labs Inc	Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
US7858121B2 (en) *	2003-12-31	2010-12-28	Cima Labs, Inc.	Effervescent oral fentanyl dosage form and methods of administering fentanyl
CA2549642C (en) *	2003-12-31	2012-10-30	Cima Labs Inc.	Effervescent oral opiate dosage forms and methods of administering opiates
JP5179757B2 (ja) *	2004-02-17	2013-04-10	トランセプトファーマシューティカルズ，インコーポレイティド	口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
WO2006009975A2 (en) *	2004-06-22	2006-01-26	Maxim Pharmaceuticals, Inc.	Histamine to treat disorders affecting muscle function
US20060004035A1 (en) *	2004-06-25	2006-01-05	Cephalon, Inc.	System for identification of a pharmaceutical product
US20060029665A1 (en) *	2004-08-03	2006-02-09	Transoral Pharmaceuticals, Inc.	Pilocarpine compositions and methods of use thereof
WO2006073514A2 (en) *	2004-08-25	2006-07-13	Tufts University	Compositions, methods and kits for repressing virulence in gram positive bacteria
US20060051413A1 (en) *	2004-09-08	2006-03-09	Chow Sing S M	Method of enhancing absorptions of transmucosal administration formulations
US20050196517A1 (en) *	2005-02-14	2005-09-08	Mars, Incorporated	Edible product having discrete regions with different heats of solution
US20070287740A1 (en) *	2005-05-25	2007-12-13	Transcept Pharmaceuticals, Inc.	Compositions and methods of treating middle-of-the night insomnia
EP1883408A4 (de) *	2005-05-25	2009-11-11	Transcept Pharmaceuticals Inc	Feste zusammensetzungen und verfahren zur behandlung von schlaflosigkeit mitten in der nacht
US20070225322A1 (en) *	2005-05-25	2007-09-27	Transoral Pharmaceuticals, Inc.	Compositions and methods for treating middle-of-the night insomnia
US20070104763A1 (en) *	2005-11-10	2007-05-10	Navinta Llc	Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8497258B2 (en)	2005-11-12	2013-07-30	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en)	2005-11-12	2014-03-25	The Regents Of The University Of California	Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en)	2005-11-12	2012-12-04	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8535714B2 (en)	2006-01-06	2013-09-17	Acelrx Pharmaceuticals, Inc.	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en)	2006-01-06	2014-06-17	Acelrx Pharmaceuticals, Inc.	Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en)	2006-01-06	2013-01-22	Acelrx Pharmaceuticals, Inc.	Drug dispensing device with flexible push rod
US8252328B2 (en) *	2006-01-06	2012-08-28	Acelrx Pharmaceuticals, Inc.	Bioadhesive drug formulations for oral transmucosal delivery
US8252329B2 (en)	2007-01-05	2012-08-28	Acelrx Pharmaceuticals, Inc.	Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en)	2006-01-06	2012-06-19	Acelrx Pharmaceuticals, Inc.	Small-volume oral transmucosal dosage forms
US9289583B2 (en) *	2006-01-06	2016-03-22	Acelrx Pharmaceuticals, Inc.	Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) *	2007-01-05	2015-06-30	Aceirx Pharmaceuticals, Inc.	Storage and dispensing devices for administration of oral transmucosal dosage forms
US8865743B2 (en)	2006-01-06	2014-10-21	Acelrx Pharmaceuticals, Inc.	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
KR101191322B1 (ko) *	2006-04-07	2012-10-16	메리온 리서치 Ⅲ 리미티드	증진제를 함유하는 고형 경구용 투여 제형
US20070260491A1 (en) *	2006-05-08	2007-11-08	Pamela Palmer	System for delivery and monitoring of administration of controlled substances
US20070293581A1 (en) *	2006-06-05	2007-12-20	Malcolm Hill	Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
EP2040731A4 (de) *	2006-06-09	2010-05-19	Merrion Res Iii Ltd	Feste orale dosierform mit einem verstärkungsmittel
US20070299687A1 (en) *	2006-06-23	2007-12-27	Pamela Palmer	Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US8642016B2 (en)	2006-07-21	2014-02-04	Jsrnti, Llc	Medicinal delivery system, and related methods
RU2504377C2 (ru)	2006-07-21	2014-01-20	БайоДеливери Сайенсиз Интэнэшнл, Инк.	Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
US8158609B1 (en)	2006-11-02	2012-04-17	Novartis Ag	Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
MX2009005671A (es) *	2006-12-01	2009-06-08	Cima Labs Inc	Forma de dosificacion de nicotina transmucosal oral.
US20090214442A1 (en) *	2006-12-01	2009-08-27	Cephalon, Inc.	Oral Transmucosal Nicotine Dosage Form
EP1938756A1 (de) *	2006-12-29	2008-07-02	Qiagen GmbH	Verfahren und Materialen zur gesteuerten Freisetzung einer biologischen Probe
WO2008091592A1 (en)	2007-01-22	2008-07-31	Targacept, Inc.	Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2008100434A1 (en)	2007-02-09	2008-08-21	Durect Corporation	Transoral dosage forms comprising sufentanil and naloxone
WO2008098195A2 (en) *	2007-02-09	2008-08-14	Todd Maibach	Film comprising nitroglycerin
US20100172991A1 (en) *	2007-06-08	2010-07-08	Henry Joseph Horacek	Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
JP2010529142A (ja) *	2007-06-08	2010-08-26	アドレネクス・ファーマシューティカルズ，インコーポレイテッド	アドレナリン調節異常症を治療する徐放性の製剤および方法
US20090004254A1 (en) *	2007-06-19	2009-01-01	Todd Maibach	Film comprising active drugs
EP2025332A1 (de) *	2007-08-13	2009-02-18	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Auf Ton basierende aromatisierte therapeutische Zusammensetzung
EP2214679B1 (de)	2007-11-13	2019-03-27	Meritage Pharma, Inc.	Kortikosteroidzusammensetzungen
US20090123551A1 (en) *	2007-11-13	2009-05-14	Meritage Pharma, Inc.	Gastrointestinal delivery systems
US20100216754A1 (en) *	2007-11-13	2010-08-26	Meritage Pharma, Inc.	Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) *	2007-11-13	2009-06-04	Meritage Pharma, Inc.	Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) *	2008-04-21	2009-10-22	Meritage Pharma, Inc.	Treating eosinophilic esophagitis
CN107096012A (zh) *	2008-05-07	2017-08-29	诺和诺德股份有限公司	肽的组合物及其制备方法
CN102056568B (zh)	2008-06-04	2013-08-21	高露洁-棕榄公司	具有气穴系统的口腔护理器具
US20100055050A1 (en) *	2008-08-30	2010-03-04	Kathleen Moore	Nicotine chewing gum on a stick
US8945592B2 (en)	2008-11-21	2015-02-03	Acelrx Pharmaceuticals, Inc.	Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP2385769A4 (de) *	2008-12-15	2014-08-20	Valeant Pharmaceuticals Luxembourg S R L	Schnell lösliche vitaminformulierung und verfahren zu ihrer anwendung
US20100215743A1 (en) *	2009-02-25	2010-08-26	Leonard Thomas W	Composition and drug delivery of bisphosphonates
US20110097401A1 (en) *	2009-06-12	2011-04-28	Meritage Pharma, Inc.	Methods for treating gastrointestinal disorders
RU2015144851A (ru)	2009-06-18	2019-01-10	Серенити Фармасьютикалз, Элэлси	Безопасное применение десмопрессина
US8475832B2 (en) *	2009-08-07	2013-07-02	Rb Pharmaceuticals Limited	Sublingual and buccal film compositions
EP2498763A4 (de)	2009-11-09	2015-10-07	Spotlight Technology Partners Llc	Hydrogele auf polysaccharidbasis
CN102695501A (zh)	2009-11-09	2012-09-26	聚光灯技术合伙有限责任公司	碎裂水凝胶
US20110182985A1 (en) *	2010-01-28	2011-07-28	Coughlan David C	Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) *	2010-03-26	2011-09-29	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US8623409B1 (en)	2010-10-20	2014-01-07	Tris Pharma Inc.	Clonidine formulation
EP2661273A4 (de)	2011-01-07	2014-06-04	Merrion Res Iii Ltd	Pharmazeutische zusammensetzungen aus eisen zur oralen verabreichung
MX352959B (es)	2011-08-18	2017-12-15	Biodelivery Sciences Int Inc	Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
SMT202100546T1 (it)	2011-09-19	2021-11-12	Orexo Ab	Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
US9901539B2 (en)	2011-12-21	2018-02-27	Biodelivery Sciences International, Inc.	Transmucosal drug delivery devices for use in chronic pain relief
UA115139C2 (uk)	2011-12-28	2017-09-25	Поузен Інк.	Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
SMT201800585T1 (it)	2012-05-02	2019-01-11	Orexo Ab	Nuova composizione di alfentanil per il trattamento di dolore acuto
US20160051496A1 (en) *	2014-08-20	2016-02-25	Tsu-I Catherine Wang	Oral Transmucosal Compositions Including C-SERMs for Treating Female Infertility
US20160051495A1 (en) *	2014-08-20	2016-02-25	Professional Compounding Centers Of America	Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
US20170281713A1 (en)	2014-08-29	2017-10-05	Albert B. Crum	A method for side effect reduction in the use of statins via physiologically synthesized glutathione
US10265384B2 (en)	2015-01-29	2019-04-23	Novo Nordisk A/S	Tablets comprising GLP-1 agonist and enteric coating
US9744239B2 (en)	2015-01-30	2017-08-29	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en)	2015-01-30	2017-08-29	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en)	2015-01-30	2017-09-05	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en)	2015-01-30	2017-06-27	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en)	2015-01-30	2018-04-10	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en)	2015-01-30	2018-03-27	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US11191735B2 (en)	2015-03-13	2021-12-07	Nutrition 21, Llc	Arginine silicate for periodontal disease
US20170135969A1 (en)	2015-11-12	2017-05-18	Jds Therapeutics, Llc	Topical arginine-silicate-inositol for wound healing
CN109890384A (zh)	2016-09-01	2019-06-14	Jds治疗有限公司	生物素镁组合物和使用方法
MX389336B (es)	2016-11-15	2025-03-20	Klaria Pharma Holding Ab	Formulacion farmaceutica.
GB201709141D0 (en)	2017-06-08	2017-07-26	Klaria Pharma Holding Ab	Pharmaceutical formulation
GB201808462D0 (en)	2018-05-23	2018-07-11	Klaria Pharma Holding Ab	Pharmaceutical formulation
MX2021005213A (es)	2018-11-02	2021-09-08	Nutrition 21 Llc	Composiciones que contienen complejos de silicato de arginina estabilizado con inositol y inositol para mejorar funciones cognitivas en jugadores de videojuegos.
IL294021A (en)	2019-12-16	2022-08-01	Nutrition 21 Llc	Methods of production of arginine-silicate complexes
US11918689B1 (en)	2020-07-28	2024-03-05	Tris Pharma Inc	Liquid clonidine extended release composition

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US122507A (en) *		1872-01-02		Improvement in medical compounds or worm-candies
US1971560A (en) *	1928-10-22	1934-08-28	Parker Meyer Dennis Company	Candy and holder therefor
US2096611A (en) *	1935-02-07	1937-10-19	Parker Meyer Dennis Company	Confection
US2208120A (en) *	1938-03-02	1940-07-16	William B Coleman	Pharmaceutical preparation and method of making same
US2246778A (en) *	1939-12-21	1941-06-24	Edward E Cahoon	Safety handle for confections
US2295042A (en) *	1941-08-25	1942-09-08	Robert L Llewellyn	Fish plug
GB550296A (en) *	1941-11-17	1943-01-01	British Oxygen Co Ltd	Improvements in or relating to the administration of inhalant gas mixtures
US2323656A (en) *	1942-07-28	1943-07-06	Helfenstein John	Fishhook
US2508560A (en) *	1946-10-22	1950-05-23	Mozel A Adams	Fishing lure
GB628709A (en) *	1947-10-06	1949-09-02	William Edmondson	An appliance for the production and administration of gas-vapour mixtures
US2488272A (en) *	1948-08-06	1949-11-15	Harry E Davis	Cellophane stick and method of making it
US2469589A (en) *	1948-09-20	1949-05-10	Toy Pop Corp	Confection with support therefor
GB646680A (en) *	1948-10-27	1950-11-29	William Edmondson	Apparatus for mixing the vapour of a volatile anaesthetic with air
US2915061A (en) *	1956-12-24	1959-12-01	Cyprane Ltd	Volatile anaesthetic vaporising apparatus
US2926121A (en) *	1957-03-20	1960-02-23	American Home Prod	Therapeutic candy-like product and its preparation
US2857908A (en) *	1957-04-26	1958-10-28	Leslie S Cornfield	Candy coated tongue depressor
US2897624A (en) *	1958-06-27	1959-08-04	Frederick O Yakel	Conservation fishhooks
US2963404A (en) *	1958-09-05	1960-12-06	Pfizer & Co C	Tannate candy making, and product
US3210247A (en) *	1960-04-16	1965-10-05		Anti-epileptic i-cyclohexyl-z-methyl- aiviino propane salt of phenyl ethyl barbituric acid
CH410963A (de) *	1960-07-28	1966-04-15	Hommel Ag	Verfahren zur Herstellung von 5-Allyl-5-(B-oxypropyl)-barbitursäure
GB968054A (en) *	1962-02-15	1964-08-26	Cyprane Ltd	Improvements in volatile anaesthetic vaporising apparatus
US3114642A (en) *	1962-04-20	1963-12-17	Corn Products Co	Hard candy and process for making same
US3264115A (en) *	1962-07-10	1966-08-02	Harry E Davis	Safety lollipop
US3493652A (en) *	1962-09-14	1970-02-03	Charles W Hartman	Controlled release medicament
US3271256A (en) *	1963-03-21	1966-09-06	Richardson Merrell Inc	Chloroform in hard candy
US3172179A (en) *	1963-08-12	1965-03-09	John V Schafer	Collar fastener
GB1083896A (en) *	1964-04-30	1967-09-20	Dunster Lab Ltd	Vehicles for administering drugs
GB1071659A (en) *	1964-06-09	1967-06-07	Cyprane Ltd	Improvements in or relating to volatile anaesthetic vaporising apparatus
US3344030A (en) *	1964-06-15	1967-09-26	American Home Prod	Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
US3341414A (en) *	1964-08-27	1967-09-12	Merck & Co Inc	N-cyclohexylsulfamate solubilized medication
GB1171691A (en) *	1967-02-24	1969-11-26	Forest Laboratories	Lond-Acting Oral Carrier
US3438787A (en) *	1967-03-09	1969-04-15	Atlas Chem Ind	Sugarless confection
US3418743A (en) *	1967-05-02	1968-12-31	Roy H. Halvorsen	Fish lure with retractable hooks
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3556811A (en) *	1969-08-11	1971-01-19	Walton J Smith	Low-fermentability hard candy
US3697641A (en) *	1970-01-02	1972-10-10	Gerhard W Ahrens	Nonhygroscopic non-sugarbase noncariogenic-vitamin c releasable base material for use in the preparation of suckable tablets,lozenges and chocolate
US3622352A (en) *	1970-04-30	1971-11-23	Philip Morris Inc	Edible compositions and method for coating them
US3996934A (en) *	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3738845A (en) *	1972-01-07	1973-06-12	Pfizer	Process for the manufacture of sugarless confections
FI50578C (fi) *	1972-09-05	1976-05-10	Haemeen Anttila Yrjoe Sakari	Syöksykoukuilla varustettu uistin
US3867927A (en) *	1974-06-13	1975-02-25	Patrick F Hergott	Tongue blade sucker
US3943928A (en) *	1974-09-25	1976-03-16	Lariccia Anthony H	Eliminating the safety hazard in oral dissolution of a solid
US4093709A (en) *	1975-01-28	1978-06-06	Alza Corporation	Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) *	1975-01-28	1978-12-26	Alza Corporation	Structured orthoester and orthocarbonate drug delivery devices
US4168308A (en) *	1976-03-12	1979-09-18	Apoteksvarucentralen Vitrum Ab	Composition for enhancing the administration of pharmacologically active agents
US4060084A (en) *	1976-09-07	1977-11-29	Alza Corporation	Method and therapeutic system for providing chemotherapy transdermally
DE2712161C2 (de) *	1977-03-19	1983-01-05	Blendax-Werke R. Schneider Gmbh & Co, 6500 Mainz	Zahn- und Mundpflegemittel
DD132404B1 (de) *	1977-08-12	1983-04-27	Roland Schubert	Verfahren zur herstellung eines arzneimitteltraegers
US4139627A (en) *	1977-10-06	1979-02-13	Beecham Inc.	Anesthetic lozenges
EP0001907B1 (de) *	1977-11-07	1981-02-11	Beecham Inc.	Anästhetische Lutschtabletten und Verfahren zu ihrer Herstellung
JPS5562012A (en) *	1978-11-06	1980-05-10	Teijin Ltd	Slow-releasing preparation
US4225627A (en) *	1979-01-08	1980-09-30	A. E. Staley Manufacturing Company	Demolding confections with steam
GB2042888B (en) *	1979-03-05	1983-09-28	Teijin Ltd	Preparation for administration to the mucosa of the oral or nasal cavity
US4291015A (en) *	1979-08-14	1981-09-22	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing a vasodilator
US4307075A (en) *	1979-09-13	1981-12-22	American Home Products Corporation	Topical treatment of aphthous stomatitis
US4241092A (en) *	1979-10-26	1980-12-23	General Foods Corporation	Gasified candy dispersed in a matrix of sorbitol
US4335147A (en) *	1980-03-12	1982-06-15	Helmut Sollich	Method for making confections
US4311722A (en) *	1980-07-11	1982-01-19	Life Savers, Inc.	High fructose hard candy
JPS5758615A (en) *	1980-09-26	1982-04-08	Nippon Soda Co Ltd	Film agnent and its preparation
JPS5843368B2 (ja) *	1980-10-30	1983-09-27	日東電工株式会社	消炎鎮痛貼付剤
US4346709A (en) *	1980-11-10	1982-08-31	Alza Corporation	Drug delivery devices comprising erodible polymer and erosion rate modifier
IL61721A (en) *	1980-12-16	1984-03-30	Blank Izhak	Nitroglycerin preparations
JPS6059207B2 (ja) *	1981-03-13	1985-12-24	日東電工株式会社	複合製剤の製法
AU8533582A (en) *	1981-07-10	1984-01-12	Reckitt & Colman Products Limited	Stable solutions of buprenorphine
SU1011126A1 (ru) *	1981-07-14	1983-04-15	Всесоюзный научно-исследовательский и испытательный институт медицинской техники	Средство дл лечени сахарного диабета
US4372942A (en) *	1981-08-13	1983-02-08	Beecham Inc.	Candy base and liquid center hard candy made therefrom
US4452825A (en) *	1982-09-01	1984-06-05	Nabisco Brands, Inc.	Sorbitol-containing hard candy
CA1208558A (en) *	1982-10-07	1986-07-29	Kazuo Kigasawa	Soft buccal
US4642231A (en) *	1983-07-20	1987-02-10	Warner-Lambert Company	Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
US4749575A (en) *	1983-10-03	1988-06-07	Bio-Dar Ltd.	Microencapsulated medicament in sweet matrix
US4551329A (en) *	1984-01-20	1985-11-05	Joan Harris	Oral medicament lollipop
US4863737A (en) *	1985-05-01	1989-09-05	University Of Utah	Compositions and methods of manufacture of compressed powder medicaments
US4588580B2 (en) *	1984-07-23	1999-02-16	Alaz Corp	Transdermal administration of fentanyl and device therefor
US4818539A (en) *	1985-02-05	1989-04-04	Warner-Lambert Company	Ingestible aggregate and delivery system prepared therefrom
US4671953A (en) *	1985-05-01	1987-06-09	University Of Utah Research Foundation	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
DE68922225T2 (de) *	1985-05-01	1995-08-10	Anesta Corp., Salt Lake City, Utah	Verdichtete pulverheilmittel.
US5288497A (en) *	1985-05-01	1994-02-22	The University Of Utah	Compositions of oral dissolvable medicaments
US4695463A (en) *	1985-05-24	1987-09-22	Warner-Lambert Company	Delivery system for active ingredients and preparation thereof
US4764378A (en) *	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
FR2611501B1 (fr) *	1987-03-04	1991-12-06	Corbiere Jerome	Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention

1989
- 1989-09-05 US US07/403,751 patent/US5288497A/en not_active Expired - Lifetime
1990
- 1990-08-03 EP EP90912733A patent/EP0490916B1/de not_active Expired - Lifetime
- 1990-08-03 AT AT94111352T patent/ATE177007T1/de not_active IP Right Cessation
- 1990-08-03 DK DK90912733.4T patent/DK0490916T3/da active
- 1990-08-03 DK DK94111352T patent/DK0630647T3/da active
- 1990-08-03 JP JP2512229A patent/JP2717024B2/ja not_active Expired - Lifetime
- 1990-08-03 ES ES94111352T patent/ES2133448T3/es not_active Expired - Lifetime
- 1990-08-03 ES ES90912733T patent/ES2077686T3/es not_active Expired - Lifetime
- 1990-08-03 CA CA002066423A patent/CA2066423C/en not_active Expired - Lifetime
- 1990-08-03 AT AT90912733T patent/ATE129148T1/de not_active IP Right Cessation
- 1990-08-03 DE DE69023143T patent/DE69023143T2/de not_active Expired - Lifetime
- 1990-08-03 EP EP94111352A patent/EP0630647B1/de not_active Expired - Lifetime
- 1990-08-03 WO PCT/US1990/004384 patent/WO1991003237A1/en not_active Ceased
- 1990-08-03 AU AU62877/90A patent/AU645265B2/en not_active Ceased
- 1990-08-03 DE DE69032982T patent/DE69032982T2/de not_active Expired - Lifetime
1992
- 1992-03-04 NO NO920857A patent/NO304348B1/no not_active IP Right Cessation
1994
- 1994-02-18 AU AU55218/94A patent/AU668004B2/en not_active Expired

Also Published As

Publication number	Publication date
DE69032982D1 (de)	1999-04-08
JPH05503917A (ja)	1993-06-24
ATE129148T1 (de)	1995-11-15
DK0490916T3 (da)	1996-03-04
EP0490916A1 (de)	1992-06-24
NO920857D0 (no)	1992-03-04
DE69023143D1 (de)	1995-11-23
ES2077686T3 (es)	1995-12-01
EP0490916B1 (de)	1995-10-18
NO920857L (no)	1992-04-06
ES2133448T3 (es)	1999-09-16
AU668004B2 (en)	1996-04-18
CA2066423C (en)	1998-04-14
JP2717024B2 (ja)	1998-02-18
WO1991003237A1 (en)	1991-03-21
EP0630647B1 (de)	1999-03-03
AU645265B2 (en)	1994-01-13
EP0630647A1 (de)	1994-12-28
US5288497A (en)	1994-02-22
DK0630647T3 (da)	1999-10-04
EP0490916A4 (en)	1992-08-12
AU6287790A (en)	1991-04-08
AU5521894A (en)	1994-04-28
DE69032982T2 (de)	1999-08-26
ATE177007T1 (de)	1999-03-15
CA2066423A1 (en)	1991-03-06
DE69023143T2 (de)	1996-03-28

Legal Events

Date	Code	Title	Description
2010-08-16	MK1K	Patent expired

Publication	Publication Date	Title
NO304348B1 (no)	1998-12-07	FremgangsmÕte for fremstilling av en medikamentinneholdende doseringsform for bruk ved transmucosal administrering
US5785989A (en)	1998-07-28	Compositions and methods of manufacturing of oral dissolvable medicaments
US5132114A (en)	1992-07-21	Compositions and methods of manufacture of compressed powder medicaments
US4863737A (en)	1989-09-05	Compositions and methods of manufacture of compressed powder medicaments
EP0487520B1 (de)	1995-04-12	Verdichtete pulverheilmittel
JP2749198B2 (ja)	1998-05-13	経粘膜性剤形
US20020160043A1 (en)	2002-10-31	Compositions and method of manufacture for oral dissolvable dosage forms
DK2361081T3 (en)	2016-08-15	MULTIPLE INTRAORAL DOSAGE FORM AND USE THEREOF
US5855908A (en)	1999-01-05	Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
US6197334B1 (en)	2001-03-06	Lozenge and method of making
EP0493380B1 (de)	1997-10-29	Verfahren und zusammensetzungen zur verabreichung von lipophilen heilmitteln in einer dosierung nach der gewünschten wirkung
AU641127B2 (en)	1993-09-16	Compressed powder medicaments
CA1339190C (en)	1997-07-29	Compositions and methods of manufacture of compressed powder medicaments
AU684888B2 (en)	1998-01-08	Method and compositions for noninvasive dose to effect administration of lipophilic drugs
CA1339075C (en)	1997-07-29	Methods and compositions for noninvasive dose-to-effect administration of lipophilic drugs